147 results on '"Guttman-Yassky, Emma"'
Search Results
2. Beyond Avoidance: Advanced Therapies for Contact Dermatitis
3. A clinician’s guide to pediatric and adolescent alopecia areata treatments
4. Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations
5. Regulatory T-cell dysfunction and cutaneous exposure to Staphylococcus aureus underlie eczema in DOCK8 deficiency
6. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
7. Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa
8. Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines
9. Diversity of atopic dermatitis and selection of immune targets
10. Melanoma clinicopathological groups characterized and compared with dermoscopy and reflectance confocal microscopy
11. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo
12. The role of Janus kinase signaling in the pathology of atopic dermatitis
13. Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis
14. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis
15. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort
16. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
17. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
18. Atopic Dermatitis Yardstick update
19. Oral Janus kinase inhibitors for atopic dermatitis
20. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
21. Repurposing DPP4 Inhibition to Improve Hair Follicle Activation and Regeneration
22. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
23. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study
24. Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures
25. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
26. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets
27. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients
28. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
29. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
30. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study
31. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients
32. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
33. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
34. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation
35. Real-world persistence with dupilumab among adults with atopic dermatitis
36. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
37. A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis
38. Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity
39. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis
40. Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation
41. Alopecia Areata Is Associated with Atopic Diathesis: Results from a Population-Based Study of 51,561 Patients
42. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
43. Atopic Dermatitis Endotypes Based on Allergen Sensitization, Reactivity to Staphylococcus aureus Antigens, and Underlying Systemic Inflammation
44. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
45. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
46. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
47. Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema
48. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
49. Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis
50. The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.